BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30926649)

  • 1. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with
    Jadvar H; Velez EM; Desai B; Ji L; Colletti PM; Quinn DI
    J Nucl Med; 2019 Nov; 60(11):1524-1530. PubMed ID: 30926649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
    Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI
    J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
    Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
    J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLUT1 expression in high-risk prostate cancer: correlation with
    Meziou S; Ringuette Goulet C; Hovington H; Lefebvre V; Lavallée É; Bergeron M; Brisson H; Champagne A; Neveu B; Lacombe D; Beauregard JM; Buteau FA; Riopel J; Pouliot F
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):441-448. PubMed ID: 31932660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of
    Fourquet A; Rosenberg A; Mena E; Shih JJ; Turkbey B; Blain M; Bergvall E; Lin F; Adler S; Lim I; Madan RA; Karzai F; Gulley JL; Dahut WL; Wood BJ; Chang R; Levy E; Choyke PL; Lindenberg L
    J Nucl Med; 2022 May; 63(5):735-741. PubMed ID: 34475237
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
    Fox JJ; Gavane SC; Blanc-Autran E; Nehmeh S; Gönen M; Beattie B; Vargas HA; Schöder H; Humm JL; Fine SW; Lewis JS; Solomon SB; Osborne JR; Veach D; Sawyers CL; Weber WA; Scher HI; Morris MJ; Larson SM
    JAMA Oncol; 2018 Feb; 4(2):217-224. PubMed ID: 29121144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
    Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
    Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma.
    Chun YJ; Jeung HC; Park HS; Park JS; Rha SY; Choi HJ; Lee JH; Jeon TJ
    Yonsei Med J; 2019 Jul; 60(7):604-610. PubMed ID: 31250573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Comparison of
    Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
    J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.